Scarica l'app Stockscreener
4.60
1.77%
0.08
Dopo l'orario di chiusura:
4.51
-0.09
-1.96%
Precedente Chiudi:
$4.52
Aprire:
$4.55
Volume 24 ore:
323.77K
Relative Volume:
0.45
Capitalizzazione di mercato:
$124.69M
Reddito:
-
Utile/perdita netta:
$-49.81M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-42.93M
1 W Prestazione:
-4.96%
1M Prestazione:
-68.12%
6M Prestazione:
-63.11%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.41
$4.75
Intervallo di 1 settimana:
$4.36
$4.90
Portata 52W:
$3.61
$24.00
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Confronta ANRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ANRO | 4.60 | 124.69M | 0 | -49.81M | -42.93M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
FY2024 EPS Estimate for Alto Neuroscience Boosted by Analyst - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - PR Newswire
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Alto Neuroscience, Inc. (ANRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Alto Neuroscience, Linkage Global, Pixie Dust: Top 3 Stocks With Explosive Retail Follower Growth Last Week - Barchart
Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Up 29.9% in October - MarketBeat
Q1 EPS Estimates for Alto Neuroscience Lowered by Wedbush - MarketBeat
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade - MSN
William Blair Has Negative Outlook for ANRO FY2028 Earnings - MarketBeat
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience sinks as ALTO-100 misses goal in MDD - The Pharma Letter
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Yahoo Finance
RODMAN&RENSHAW Lowers Alto Neuroscience (NYSE:ANRO) to Hold - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Alto depression drug failure sends shares plunging 66% - Green Market Report
Gold Moves Lower; AT&T Earnings Top Views - MSN
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
2024-10-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect | NYSE:ANRO | Press Release - Stockhouse Publishing
Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed - Investing.com
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade (NYSE:ANRO) - Seeking Alpha
Alto Hits The Wrong Note In Depression - Scrip
Alto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO) - MarketBeat
Alto Neuroscience shares PT slashed by Baird following ALTO-100 failure - Investing.com
Alto Neuroscience Stock Plummets Pre-Market After MDD Drug Trial Misses Primary Endpoint, Grabs Retail Attention - Barchart
Robert W. Baird Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $10.00 - MarketBeat
Alto hits new low as depression drug flunks key test - Yahoo Finance
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint - Clinical Trials Arena
Alto Neuroscience (NYSE:ANRO) Downgraded to "Neutral" at Wedbush - MarketBeat
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO - BioSpace
Alto Neuroscience reports setback in depression drug trial By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Trading 1.6% HigherShould You Buy? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Up 1.6% – Here’s What Happened - Defense World
Dow Tumbles Over 250 Points; Boeing Posts Q3 LossBoeing (NYSE:BA) - Benzinga
Alto Neuroscience stock craters 57% post-market on failed study - MSN
Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint - TipRanks
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):